The research analysts working in the Piper Sandler managed to reduce the 2022 Q1 EPS for the shares of the Moderna Company (NASDAQ: MRNA) in their research report of Thursday, 6th May. E. Tenthoff, an analyst of Piper Sandler, anticipated that the shares of the company will be earning an EPS of $5.38, which has decreased from $5.81, which was the previous forecast of the brokerage. Piper Sandler currently issued a rating of “overweight” and a target price of $231.00 on the shares of MRNA stock. MRNA stock has last issued its earnings results of a quarter on Thursday, 6th May.
More Details About The MRNA Stock
The company has an EPS of $2.84 for this quarter. They successfully managed to beat the average estimate of $2.04 by Thomson Reuters by around $0.80. MRNA stock has managed to have $1.94 bn as its revenue of the quarter. The consensus estimate was around $2.48 bn. The company has a 242.73% negative net margin and a 28.11% negative equity return. The revenue of the company increased by 24112.5% during this quarter on a Y-O-Y basis. During such a similar quarter last year, the company earned an EPS of $0.35.
MRNA stock has been a subject of anticipation for various research analysts. Morgan Stanley decreased the price target from $201.00 – $190.00 while setting a rating of “equal weight” on the shares of the company in their research report on Friday. Brookline Management increased the target price from $180.00 – $205.00 while setting a rating of “buy” on the shares of the company in their research report of Thursday, 4th March. Wells Fargo raised the target price from $129.00 -$145.00 while issuing a rating of “overweight” on the shares of the company in their research report of Monday 1st February.
